The promise of DNA damage response inhibitors for the treatment of glioblastoma

Glioblastoma (GBM), the most aggressive primary brain tumor, has a dismal prognosis. Despite our growing knowledge of genomic and epigenomic alterations in GBM, standard therapies and outcomes have not changed significantly in the past two decades. There is therefore an urgent unmet need to develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Majd, Nazanin K, Yap, Timothy A, Koul, Dimpy, Balasubramaniyan, Veerakumar, Li, Xiaolong, Khan, Sabbir, Gandy, Katilin S, Yung, W K Alfred, de Groot, John F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954093/
https://www.ncbi.nlm.nih.gov/pubmed/33738447
http://dx.doi.org/10.1093/noajnl/vdab015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954093/
https://www.ncbi.nlm.nih.gov/pubmed/33738447
http://dx.doi.org/10.1093/noajnl/vdab015

Ejemplares similares